Complete Oral nutritional Supplements: Compliance, Palatability, Tolerance In Healthy Volunteers

Pauline Uí Dhuibhir¹, Lorraine Spotten², Brenda O’Connor³, Niamh O’Donoghue⁴, Declan Walsh⁵*

¹Research Nurse, Academic Department of Palliative Medicine, Our Lady’s Hospice & Care Services Harold’s Cross,Dublin 6W.
²Lorraine Spotten, Dietitian, Our Lady’s Hospice & Care Services Harold’s Cross, Dublin 6W.
³Brenda O’Connor, Consultant in Palliative Medicine.
⁴Niamh O’Donoghue, Research Fellow.
⁵Declan Walsh, Professor of Palliative Medicine, Our Lady’s Hospice & Care Services Harold’s Cross,Dublin 6W.

Abstract

Introduction: Malnutrition is common in acute and chronic illness. Oral Nutritional Supplements (ONS) augment oral intake when food consumption is insufficient. All new ONS require acceptability testing prior to human use. ONS success depends on patient acceptability. This acceptability study examined 1) palatability, 2) compliance 3) gastrointestinal (GI) tolerance of a product range of six ONS in healthy volunteers.

Methods: The study design met the standardised clinical safety requirements outlined in Directive 2001/20/EC of the European Parliament and Council, (2001) for the conduct of acceptability studies of medicinal products prior to human use. ONS were taste-tested for Palatability by sensory panels. Volunteers taste-tested ONS daily for thirty days for Compliance and GI Tolerance.

Results: Palatability (n=20): The mean Palatability rating for all six products was 6 (SD +/-1.5); (1= dislike extremely; 9= like extremely). Compliance evaluation (n=134) showed ≥90% of volunteers consumed the prescribed ONS amount for the entire thirty days. GI Tolerance (n=134) was excellent with side effects mild in nature and of short duration.

Conclusion: This acceptability study demonstrates a suitable methodology that adheres to EU clinical safety requirements. Palatability and Compliance were uniformly high, consistent and sustained. GI side effects were uncommon, mild and brief. The tested ONS were palatable, acceptable and well tolerated in healthy adults.

Keywords: Cachexia; Compliance; Malnutrition; Oral Nutritional Supplements; Palatability; Tolerance.

Introduction

Malnutrition is common in many acute and chronic illnesses. It is defined as either a low BMI (<18.5kg/m2), or a combination of unintended weight loss together with either a low BMI (age specific) or a low Free Fat Mass Index (gender specific) [1, 2]. Consequences include compromised immune response, fatigue, impaired wound healing and reduced muscle strength. Cachexia occurs in multiple disease processes and is characterised by loss of skeletal muscle mass (with or without fat mass loss), abnormal metabolism and reduced dietary intake which is accompanied by weight loss and functional decline [3]. Cachexia and malnutrition in cancer, for example, are poor prognostic indicators and can reduce tolerance to anti-cancer therapy, impair patient outcomes and reduce survival [4, 5].

Oral Nutritional Supplements (ONS) are defined as “multi-nutrient liquid, semi-solid or powder products that provide macronutrients and micronutrients with the aim of increasing oral nutritional intake”. They are important in modern healthcare. Typically they augment food intake if insufficient and are frequently recommended for people who are undernourished or at risk of malnutrition. ONS can improve quality of life in cancer cachexia, but do not effect survival [6].

Nutritionally complete ONS contain both macronutrients (carbohydrate, fat and protein) and essential micronutrients in quantities and balance that enables them (in sufficient volume) to act either as a sole nutrition source or major dietary supplement. ONS success depends on compliance, palatability and gastrointestinal (GI) tolerance [7]. The patient ONS experience is critical but subjective. Lessons learned must be incorporated into ONS clinical guidelines and practice.

Compliance is the degree to which a person adheres to a recommended treatment plan. It has been suggested that ONS may reduce the intake of ordinary diet, thus reducing their own effectiveness [8]. However, increased daily protein and/or energy intake was shown when ONS were used. Because many studies also include dietary advice in an intervention, it can be difficult to identify which factors directly influence outcomes.

ONS convenience, duration of use, GI tolerance and

Correspondence to: Declan Walsh, Professor of Palliative Medicine, Our Lady’s Hospice & Care Services Harold’s Cross, Dublin, Tel: (01) 498 6219, E-Mail: puidhuibhir[AT]OLH[DOT]ie

Received: Feb 1, 2020; Accepted: Feb 10, 2020; Published: Feb 12, 2020

Reviewed by: Conxita Mestres i Miralles
volume consumed affect overall acceptability and therefore compliance. ONS compliance varies (37%-100%) across healthcare settings and patient groups. It is lower in the acutely ill hospitalised compared to community dwelling elderly. In older patients the use of smaller volume ONS improved compliance [9-12].

As appetite is frequently impaired during any illness or chronic disease, hunger is often absent and individuals not motivated to eat. ONS palatability is therefore particularly significant for long-term compliance [13]. Palatability is influenced by many factors: aftertaste, appearance, consistency, smell, taste, temperature, and volume. Milk-based ONS products have been rated higher than juice-based products in several palatability studies [14, 15].

GI tolerance of ONS has not been widely studied. Limited evidence suggests a satisfactory profile. The most commonly reported ONS side effects include diarrhoea, loss of appetite, nausea, undesirable weight gain,16 and vomiting.20 Although these observed side effects were mild, they resulted in non-compliance ranging from 0-28%. Greater understanding of compliance, palatability and tolerance of ONS in humans will direct specific nutritional interventions and stimulate research to address malnutrition [16-23].

The aim of this study was to explore compliance, palatability and tolerance of a product range of nutritionally complete oral nutritional supplements in healthy volunteers. The methodology used complied with standardised clinical safety requirements outlined in Directive 2001/20/EC for the conduct of acceptability studies of medicinal products prior to human use [24].

**Methods**

**Aims**

This study aimed to record Compliance, Palatability and GI Tolerance of six nutritionally complete ONS products (Nualtra®, Limerick, Ireland) in healthy volunteers.

**Recruitment**

The study was conducted by Eolas International1, a market research company that specialises in sensory and laboratory research in the food sector. It complied with best practice for acceptability studies; thus ethical approval was not required in this jurisdiction. Healthy volunteers were recruited by telephone over a 3-week period and assigned to one of seven predetermined groups (Groups A-G) in a non-randomised manner. The population selected for recruitment was predominately over sixty-five to reflect those most commonly prescribed ONS.

A minimum of 20 participants with a low/low-normal body mass index (BMI) (range: 16-20kg/m2) were recruited to each volunteer group.1 Those with diabetes, or taking dietary replacement or enhancement products were excluded.

A fixed standardised fee was paid to all participants according to current ethical procedures in the study jurisdiction.

**Consent**

Participation was entirely voluntary and participants could withdraw at any time. Before the study, all participants completed a standard questionnaire to confirm that they were in good health and signed a disclaimer with regard to potential side-effects.

**Intervention**

Six ONS products (Table 1) from a single manufacturer were tested for Palatability (Group A only), Compliance (Groups B-G), and GI Tolerance (Groups B-G).

**Table 1: Oral Nutritional Supplements Tested.**

<table>
<thead>
<tr>
<th>Product</th>
<th>Flavour</th>
<th>Volume</th>
<th>Nutritional Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Milkshake</td>
<td>Vanilla</td>
<td>125ml*</td>
<td>300kcal/12g protein/36g carbohydrate/12g fat-plus complete range of vitamins &amp; minerals ****</td>
</tr>
<tr>
<td>2 Milkshake</td>
<td>Strawberry</td>
<td>200ml **</td>
<td>300kcal/20g protein/30 carbohydrate/11.2g fat-plus complete range of vitamins &amp; minerals *****</td>
</tr>
<tr>
<td>3 Milkshake</td>
<td>Vanilla</td>
<td>125g ***</td>
<td>225kcal/12.5g protein/23.5g carbohydrate/9g fat-plus complete range of vitamins &amp; minerals *****</td>
</tr>
<tr>
<td>4 Milkshake</td>
<td>Strawberry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Dessert</td>
<td>Vanilla</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Dessert</td>
<td>Strawberry</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Altraplen Compact®
**Altraplen Protein®
***Nutricrem®
****Altraplen Compact: Mono & disaccharides: Vanilla 7.9g/100ml, Strawberry 8.3g/100ml
Polysaccharides: Vanilla 24 g/100ml, Strawberry 20.5g
Sucrose: Vanilla 3.6g/100ml, Strawberry 4.05g/100ml
Lactose: <0.5g/100ml for both flavours

*****Altraplen Protein: Mono & disaccharides: 4.6g/100ml for both flavours
Polysaccharides: 10.4g/100ml for both flavours
Sucrose: 0g/100ml for both flavours
Lactose: <0.1g/100ml for both flavours

******Nutricrem: Mono & disaccharides: 9.7g/100g for both flavours
Polysaccharides: 9.1g/100g for both flavours
Saccharose: 8g/100g for both flavours
Lactose: <0.5g/100g for both flavours
Palatability

Group A formed two sensory panels (N=10 volunteers each). Participants had no formal sensory test training beforehand. They received four hours of basic sensory test training during which the key attributes to be evaluated were explained. ONS sensory testing for palatability was completed mid-morning on three occasions over a period of 7 consecutive days in a sensory research laboratory (Eolas Laboratory, Cork, Ireland): Day 1 (Immediate Overall Liking), Day 3 (Interim Overall Liking) and Day 7 (Final Overall Liking). The higher the palatability scores the more acceptable the product. The six ONS were scored for “appearance”, “smell”, “taste”, “aftertaste”, “texture” and “overall liking” on a 9-point hedonic scale (1= dislike extremely; 9= like extremely). Participants cleansed their palate with water and dry crackers between samples (Table 1). International Organisation for Standardisation (ISO) Sensory Analysis Guidelines were adhered to during the tests [25].

Compliance & Gastrointestinal Tolerance

Six groups (B, C, D, E, F & G) (N=20-23 per group) tested one ONS serving daily for Compliance and GI Tolerance for thirty days (standardised requirement in acceptability studies - European Parliament and Council 2001). Each group was assigned a single ONS in one flavour only:

- Group B: Vanilla Milkshake (Altraplen Compact®) 125ml/300kcal/12g protein
- Group C: Strawberry Milkshake (Altraplen Compact®) 125ml/300kcal/12g protein
- Group D: Vanilla Milkshake (Altraplen Protein®) 200ml/300kcal/20g protein
- Group E: Strawberry Milkshake (Altraplen Protein®) 200ml/300kcal/20g protein
- Group F: Vanilla Dessert (Nutricrem®) 125g/225kcal/12.5g protein
- Group G: Strawberry Dessert (Nutricrem®) 125g/225kcal/12.5g protein

All six ONS products contained a complete range of essential macro- and micronutrients, with minor variation between products.

Participants in each Compliance and Tolerance group were given a 30-day supply of the assigned product. They did not choose the flavour. They were asked to consume one full serving each day at home either before or between meals in addition to their usual dietary intake.

They completed a daily compliance paper diary for thirty days to record the ONS volume ingested each day; 1) Full; 2) Three Quarters; 3) Half; 4) None. They were encouraged to consume the products at their personal preferred temperature (chilled, room temperature or heated). Participants recorded the consumption temperature and whether the product was consumed unmodified or mixed with other food. The consumption of normal diet was not measured. Participants were not under direct supervision during the study, but were phoned on Days 1, 3 and 5 to prompt accurate data recording.

During the first seven days, participants also completed daily GI symptom ratings for abdominal discomfort, altered bowel habit, bloating/distension, burping/flatulence/regurgitation, and nausea/vomiting. These are listed for monitoring and reporting by the UK Government Advisory Committee on borderline Substances (Appendix 5). A researcher telephoned each participant on Days 1, 3 and 7 to ensure symptom assessments were completed. Symptom frequency, duration and severity were recorded [26].

Data Analysis and Protection

Microsoft Excel Software (Seattle, Washington, USA) was used to generate descriptive statistics. Mean palatability rating, percentage compliance and intolerance episodes were calculated. Mean onset and duration of side effects onset and duration was also determined. Free text comments were collated and reviewed. Each participant was assigned a study number to ensure confidentiality. No individually identifiable data was collected.

Results

Volunteer Characteristics

One hundred and fifty four healthy volunteers participated (n=20 in Palatability Study; n=134 in Compliance/GI Tolerance Study). 50% were male. 75% (n=115) were >65 years.

Palatability

All products and flavours were found to be acceptable (Table 2). The mean Palatability Rating (1-9) for all six products was 6 (SD +/-1.5). All products scored well on Day 1 and remained stable or improved over time (Days 3 and 7). Product texture was described as “smooth”, “creamy”, “palatable” and “nice”.

Compliance

Compliance was high. ≥90% of participants consumed the assigned volume of all six products for thirty consecutive days. The remainder consumed half or more (Table 3). The Compact ONS had the highest individual product compliance.

Table 2: Palatability Over 7 Consecutive Days.

<table>
<thead>
<tr>
<th>Product</th>
<th>Average Rating per Time-point (Range 1-9)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 1</td>
</tr>
<tr>
<td>Milkshake:</td>
<td></td>
</tr>
<tr>
<td>Strawberry (n=23)</td>
<td>6</td>
</tr>
<tr>
<td>Vanilla (n=23)</td>
<td>6</td>
</tr>
<tr>
<td>Milkshake:</td>
<td></td>
</tr>
<tr>
<td>Strawberry (n=23)</td>
<td>6</td>
</tr>
<tr>
<td>Vanilla (n=20)</td>
<td>7</td>
</tr>
<tr>
<td>Dessert:</td>
<td></td>
</tr>
<tr>
<td>Strawberry (n=23)</td>
<td>6</td>
</tr>
<tr>
<td>Vanilla (n=22)</td>
<td>6</td>
</tr>
</tbody>
</table>
When the prescribed volume was not consumed, the identified reasons for non-compliance were abdominal fullness, bloating, constipation and taste fatigue.

Across the range of six products, most (77%) consumed the ONS chilled, the remainder at room temperature. While participants could mix the product with other foods and liquids, most (93%) did not. Those who did usually added ONS to breakfast cereals, cream, fruit, milk, porridge, smoothies, toast or yogurt.

**Tolerance**

The five GI symptoms evaluated by 134 participants daily for the first 7 days resulted in 938 evaluations. The ONS were well tolerated with mild GI symptoms in a minority. In rank order of prevalence, burping/flatulence/regurgitation occurred most frequently at 4%, followed by bloating and distension (3%), altered bowel habit (2.5%), abdominal discomfort (1.5%) and finally nausea/vomiting (1%) (Table 4). Reported symptoms were mild in nature and ranged from ‘no discomfort’ to ‘slight discomfort’. The mean time to symptom onset after ingestion was 62 minutes (SD +/- 44), while mean duration was 103 minutes (SD +/- 61).

**Discussion**

Compliance, Palatability, and Tolerance of a range of six nutritionally complete ONS products were examined in 154 healthy volunteers with a low/low-normal BMI. Compliance was high for all products over thirty days and remained consistent irrespective of flavour, product, texture or volume. Self-report and limited supervision of the data collection may have influenced these results.

These results compare favourably with previous studies. A systematic review of ONS compliance, examined thirty-three studies conducted in the community setting and found a mean non-compliance rate of 19%. In our study the Compact ONS had the highest compliance, perhaps due to a smaller volume as seen in previous studies. Most participants consumed the six products chilled. Participants were not permitted to choose their preferred product or flavour. This contrasts with clinical practice where flavours are usually individually selected. Self-selection by flavour might have further increased Compliance and Palatability ratings.

Participants liked all products consistently over the seven days irrespective of the ONS flavour, product, texture (milkshake or dessert) or volume (125ml; 200ml or 125g). No one flavour or product was significantly more palatable than another. Over seven days tolerance was high with a few mild symptoms and minor discomfort recorded. Typically symptoms were uncommon, intermittent, had a rapid onset and short duration. Participants also consumed their usual diet plus the ONS during the study and this may have contributed to some GI

<table>
<thead>
<tr>
<th>Table 3: Compliance Over 30 Consecutive Days.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Milkshake: 125ml/300kcal/12g protein</strong></td>
</tr>
<tr>
<td>Strawberry (n=23)</td>
</tr>
<tr>
<td>Vanilla (n=23)</td>
</tr>
<tr>
<td><strong>Milkshake: 200ml/300kcal/20g protein</strong></td>
</tr>
<tr>
<td>Strawberry (n=23)</td>
</tr>
<tr>
<td>Vanilla (n=20)</td>
</tr>
<tr>
<td><strong>Dessert: 125g/225kcal/12.5g protein</strong></td>
</tr>
<tr>
<td>Strawberry (n=23)</td>
</tr>
<tr>
<td>Vanilla (n=22)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 4: Gastrointestinal Symptom Occurrences Over 7 Consecutive Days.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SYMPTOMS</strong></td>
</tr>
<tr>
<td><strong>MILKSHAKE: 125ml/300kcal/12g protein</strong></td>
</tr>
<tr>
<td>Strawberry (N=23)</td>
</tr>
<tr>
<td>Vanilla (N=23)</td>
</tr>
<tr>
<td><strong>MILKSHAKE: 200ml/300kcal/20g protein</strong></td>
</tr>
<tr>
<td>Strawberry (N=23)</td>
</tr>
<tr>
<td>Vanilla (N=20)</td>
</tr>
<tr>
<td><strong>DESSERT: 125g/225kcal/12.5g protein</strong></td>
</tr>
<tr>
<td>Strawberry (N=23)</td>
</tr>
<tr>
<td>Vanilla (N=22)</td>
</tr>
<tr>
<td><strong>TOTAL SYMPTOMS</strong></td>
</tr>
<tr>
<td>Total N=134</td>
</tr>
<tr>
<td>Total Evaluations = 938</td>
</tr>
</tbody>
</table>

N = Participants who experienced the symptom at any time during the 7 test days
Total number of episodes in brackets.s
symptoms like abdominal discomfort or bloating/distension. Some (5-8%) mixed the product with other foods, most often fruit or cereals. All six nutritionally complete ONS in various flavours were well tolerated and therefore may offer the opportunity to improve overall dietary intake. Offering a choice of service temperature (chilled/room temperature/warmed) may also improve palatability. Palatability is a key driver of nutritional intake. Older adults seem to prefer flavour enhanced foods. While no studies investigated sensory variety in ONS, the European Society for Parenteral and Enteral Nutrition (ESPEN) recommend a variety of flavours, temperature and consistency to achieve increased energy and nutrient intake [27-29].

This study examined a limited number of nutritionally complete ONS products from a single manufacturer for Palatability, Compliance and Tolerance in healthy volunteers who were independent and community dwelling. Results therefore may not be generalisable to specific patient groups or settings especially those with altered taste, dysphagia or fluid restrictions. Tolerance might have been worse if used in higher volumes, but no previous studies have addressed this question. Compliance diaries and tolerance questionnaires were self-administered in the home. Nevertheless this mimics the routine clinical situation for ONS use. In clinical practice, people may take ONS for months or years and consume several servings daily. In this study participants consumed one serving per day for 30 days. Results therefore might not reflect the taste fatigue that might occur with more frequent consumption or over longer timeframes. The hedonic scale used is not validated and self-report diaries and symptom self-assessments may be unreliable and influence results. ONS consumption was not directly supervised, so over-/underestimation was not monitored. Energy intake, nutritional status/risk and weight gain were not recorded and thus nutritional outcomes not assessed. Standardised payments may have influenced results.

Future studies should examine ONS Compliance, Palatability and Tolerance in specific patient groups where malnutrition is common (e.g. cancer) and over extended periods of time, where appropriate. Specific nutritional outcomes should be evaluated to ascertain the impact of ONS on prevention or reversal of malnutrition.

Conclusions

Compliance rates and Palatability scores were uniformly high and sustained over thirty days for a range of six nutritionally complete ONS in volunteers with normal/low normal BMI. Non-compliance appeared unrelated to the specific ONS product as it did not vary across products despite different volumes. GI side effects were uncommon, mild and of short duration. These specific ONS seem to be a palatable, acceptable and well-tolerated way to support nutrition in adults.

Acknowledgements

Mr Paul Gough, Nualtra Ltd., National Technology Park, Limerick for study support. Eolas Sensory Research Laboratory, 1703 Euro Business Park, Cork for recruitment and data collection.

Conflict of interest

This work was supported by Nualtra Ltd, National Technology Park, Limerick, Ireland. Prof Declan Walsh is a non-executive director of Nualtra Ltd.

References

1. World Health Organisation (2006) BMI Classification; Global Database on Body Mass Index. [View Article]


26. UK Government Advisory Committee On Borderline Substances Appendix 5. [View Article]

